NY-BORN
21.4.2021 15:14:06 CEST | Business Wire | Press release
Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever.
The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by personalization techniques to drive product engagement and understanding, create supplemental content around products and ultimately increase transaction value. Today, BORN and Alkeon announce industry veteran Stewart Mancey as Director of E-Concession & Retail Partners, joining a deep bench of global experts from multiple categories. As Director of E-Concession & Retail Partners, Stewart will work closely with Pierre Sapin (Chief Partnership Officer), Brendan Wypich (Chief Design & Product Officer), and Jean-Christophe Chopin (CEO and Founder of BORN and former ex-Verisign and *ETrade EU founder) . Mancey will work with brands and retailers on both Alkeon and BORN. His prestigious training at Harrods and knowledge of the creativity behind each retailer will lead BORN to curate purpose-led lifestyle brands using the filters of integrity, functionality, and desirability.
Stewart states, “Twenty years at Harrods has given me a wonderful experience, fabulous industry contacts, and a deep understanding of the power of curation across multiple categories. As Head of Curation for BORN and Alkeon, I’ll guide the product strategy for both, carefully curating across multiple dimensions that reflect today’s buying priorities and creating the ideal mix representing a cross-section of the best products and companies in the world. We want to take a load of sifting off of buyers and consumers and allow them to experience best-in-class product discovery powered by machine learning, delivered in a personalized experience and a beautiful environment that leverages the latest in technology.”
Stewart started his successful buying career at Harrods when he moved from the shop floor in 2003, working through the buying office in Women’s Superbrands before becoming Buyer of Eveningwear, Armani, and Ralph Lauren after three years. He eventually moved over to Menswear in 2007, where he was Senior Buyer for Men’s Superbrands & Tailoring, overseeing over £10m in renovations and delivering strong growth throughout his four years. In 2011, Stewart added the title of Head of Buying for Sports and managed the London Olympic strategy for Harrods, along with an additional £5m renovation. In 2013, Stewart took over Head of Buying for Furniture, Technology, and Toys and increased his remit in 2017 to include Homewares. After 21 incredibly successful years with Harrods, Stewart today joins BORN and its B2B extension Alkeon. Stewart will be a key player in the vital balance between designed technology and brand culture within both BORN and Alkeon’s market networks.
CEO Jean-Christophe Chopin states, “ Our ambition across BORN and Alkeon is to transform the B2B and B2C supply chains, reimagining discovery, transaction, and connection for both communities. Stewart adds critical and unique expertise to our executive leadership, which is a collection of the best minds in curation, commerce, community, and content. Stewart will contribute his years of knowledge of culture and brands, his deep understanding of the chains of commerce across multiple categories, his leading editorial expertise, and his unmatched Rolodex of brands and creators. We are delighted to have him.”
About BORN:
BORN is a holding company specializing in digital, data-led solutions to optimize retail and wholesale supply chains and reimagine discovery and transactions online. BORN owns Alkeon, a suite of B2B solutions and software products that facilitate digital transformation, as well as BORN.com, a platform that connects a global network of design-led brands and retailers. BORN has also curated and hosted the BORN Awards for 10 years in celebration of purpose led products and creativity. BORN is led by CEO Jean-Christophe Chopin, ex-founder of *ETrade EU and Verisign EU.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom